https://openbell.ai/ 2026-10-01T14:09:09.519Z hourly 1.0 https://openbell.ai/support 2026-10-01T14:09:09.519Z monthly 0.7 https://openbell.ai/privacy 2026-10-01T14:09:09.519Z monthly 0.5 https://openbell.ai/terms 2026-10-01T14:09:09.519Z monthly 0.5 https://openbell.ai/feed.json 2026-10-01T14:09:09.519Z hourly 0.8 https://openbell.ai/news/BRKR:1790863647244 2026-10-01T14:07:27.244Z daily 0.9 https://cdn.brandfetch.io/BRKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Bruker, Raises Price Target to $72 Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Bruker (NASDAQ: BRKR) and increased the price target from $70 to $72. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/POAS:1790863599893 2026-10-01T14:06:39.893Z daily 0.9 https://cdn.brandfetch.io/POAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Phaos Technology Inks $10M Securities Purchase Agreement With High West Partners Phaos Technology Holdings (NYSE American: POAS) has entered into a securities purchase agreement with High West Partners LLC, allowing the company to sell up to $10 million of its Class A ordinary shares. The agreement, dated September 28, 2026, grants Phaos the right to sell shares at prevailing market prices, subject to specific terms and NYSE listing rules. https://openbell.ai/news/CAH:1790863545100 2026-10-01T14:05:45.100Z daily 0.9 https://cdn.brandfetch.io/CAH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cardinal Health shares are trading higher after the company reaffirmed its FY27 adjusted EPS guidance above estimates. openbell Financial News https://openbell.ai/news/ABBV:1790863459114 2026-10-01T14:04:19.114Z daily 0.9 https://cdn.brandfetch.io/ABBV/w/400/h/400?c=1idopYfmtR7ZKg8QMud AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 2026 European Academy Of Dermatology And Venereology Congress AbbVie (NYSE: ABBV) presented late-breaking results from its Phase 3 Viti-Up-1 and Viti-Up-2 trials of RINVOQ (upadacitinib) for non-segmental vitiligo at the 2026 EADV Congress, demonstrating continued facial and total body repigmentation through week 76. Additionally, findings from a phototherapy substudy indicated that patients receiving RINVOQ combined with whole-body NB-UVB phototherapy had numerically higher repigmentation responses compared to those receiving RINVOQ alone. https://openbell.ai/news/OXY:1790863436939 2026-10-01T14:03:56.939Z daily 0.9 https://cdn.brandfetch.io/OXY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Occidental Petroleum shares are trading higher after Goldman Sachs upgraded its rating on the stock from Neutral to Buy and raised its price target from $63 to $69. openbell Financial News https://openbell.ai/news/SPY:1790863247001 2026-10-01T14:00:47.001Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud USA Construction Spending (MoM) For August 0.9% Vs 0.0% Est openbell Financial News https://openbell.ai/news/CYRX:1790863234676 2026-10-01T14:00:34.676Z daily 0.9 https://cdn.brandfetch.io/CYRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on CryoPort, Raises Price Target to $19 Guggenheim analyst Subbu Nambi has maintained a Buy rating on CryoPort (NASDAQ: CYRX) and raised the price target from $16 to $19. This adjustment reflects a positive outlook for the company's stock performance. https://openbell.ai/news/SPY:1790863221665 2026-10-01T14:00:21.665Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud ISM Manufacturing Prices For September 77.9 Vs 72.9 Est. openbell Financial News https://openbell.ai/news/DHR:1790863141261 2026-10-01T13:59:01.261Z daily 0.9 https://cdn.brandfetch.io/DHR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Danaher, Raises Price Target to $250 Guggenheim analyst Subbu Nambi has maintained a Buy rating on Danaher (NYSE: DHR) and increased the price target from $200 to $250. This adjustment reflects a positive outlook for the company's performance. https://openbell.ai/news/GH:1790863024298 2026-10-01T13:57:04.298Z daily 0.9 https://cdn.brandfetch.io/GH/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200 Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Guardant Health (NASDAQ: GH) and increased the price target from $190 to $200. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/GRAL:1790862912177 2026-10-01T13:55:12.177Z daily 0.9 https://cdn.brandfetch.io/GRAL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on GRAIL, Raises Price Target to $155 Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on GRAIL (NASDAQ: GRAL) and raised the price target significantly from $75 to $155. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/GOGO:1790862815544 2026-10-01T13:53:35.544Z daily 0.9 https://cdn.brandfetch.io/GOGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gogo Says Court Overturned SmartSky's $22.7M Damages Award In Its Entirety Gogo Inc. announced that the U.S. District Court for the District of Delaware has overturned a jury's $22.7 million damages award to SmartSky Networks in its entirety, stating that SmartSky failed to prove any recoverable damages. The court found the damages award was not supported by the evidentiary record and relied on unsubstantiated assumptions. This ruling is a significant development for Gogo as it seeks to resolve the matter and refocus on its core business of providing connectivity technology for aviation customers. The ruling is subject to appeal. https://openbell.ai/news/ILMN:1790862805302 2026-10-01T13:53:25.302Z daily 0.9 https://cdn.brandfetch.io/ILMN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Illumina, Raises Price Target to $305 Guggenheim analyst Subbu Nambi has maintained a Buy rating on Illumina (NASDAQ: ILMN) and raised the price target from $226 to $305. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/NTRA:1790862735886 2026-10-01T13:52:15.886Z daily 0.9 https://cdn.brandfetch.io/NTRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Natera, Raises Price Target to $475 Guggenheim analyst Subbu Nambi has maintained a Buy rating on Natera (NASDAQ: NTRA) and raised the price target from $360 to $475. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/TEM:1790862663975 2026-10-01T13:51:03.975Z daily 0.9 https://cdn.brandfetch.io/TEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $92 Guggenheim analyst Subbu Nambi has maintained a Buy rating on Tempus AI (NASDAQ: TEM) and increased the price target from $65 to $92. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/TWST:1790862531024 2026-10-01T13:48:51.024Z daily 0.9 https://cdn.brandfetch.io/TWST/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212 Guggenheim analyst Subbu Nambi has maintained a Buy rating on Twist Bioscience (NASDAQ: TWST) and raised the price target from $107 to $212. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/NXL:1790862517626 2026-10-01T13:48:37.626Z daily 0.9 https://cdn.brandfetch.io/NXL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nexalin Technology Shares Halted On Circuit Breaker To The Upside, Stock Now Up 92.76% openbell Financial News https://openbell.ai/news/WAT:1790862443172 2026-10-01T13:47:23.172Z daily 0.9 https://cdn.brandfetch.io/WAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on Waters, Raises Price Target to $490 Guggenheim analyst Subbu Nambi has maintained a Buy rating on Waters (NYSE: WAT) and increased the price target from $440 to $490. This adjustment reflects a positive outlook for the company's stock performance. https://openbell.ai/news/WGS:1790862384812 2026-10-01T13:46:24.812Z daily 0.9 https://cdn.brandfetch.io/WGS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83 Guggenheim analyst Subbu Nambi has reiterated a Buy rating on GeneDx Holdings (NASDAQ: WGS) and increased the price target from $74 to $83. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/BBUC:1790862021421 2026-10-01T13:40:21.421Z daily 0.9 https://cdn.brandfetch.io/BBUC/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Reiterates Outperform on Brookfield Business, Maintains C$40 Price Target RBC Capital analyst Bart Dziarski has reiterated an Outperform rating on Brookfield Business (TSX: BBUC) and maintained a price target of C$40. This endorsement suggests confidence in the company's performance and potential for growth. https://openbell.ai/news/LPA:1790861568279 2026-10-01T13:32:48.279Z daily 0.9 https://cdn.brandfetch.io/LPA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Logistic Properties of the Americas shares are trading higher after the company announced the closing of the previously disclosed sale of Parque Logístico Lima Sur to FIBRA Prime. openbell Financial News https://openbell.ai/news/GANX:1790861556162 2026-10-01T13:32:36.162Z daily 0.9 https://cdn.brandfetch.io/GANX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gain Therapeutics Announces Poster Presentation At International Congress Of Parkinson’s Disease And Movement Disorders, October 4-8; MDS-UPDRS Motor Scores Demonstrated Stability To Baseline Recorded At Study Entry With No Disease Progression Among The 12 Evaluable Participants; Results Support Disease-Modifying Potential Of Rexaceract Gain Therapeutics, Inc. (NASDAQ: GANX) presented a poster at the International Congress of Parkinson’s Disease and Movement Disorders, highlighting long-term data from a Phase 1b study of rexaceract. The study showed stabilization of MDS-UPDRS motor scores over 12 months among 12 evaluable participants, indicating no disease progression. The company plans to submit a new Phase 2 study protocol to the FDA soon and aims to initiate the Phase 2 clinical trial in Q1 2027. https://openbell.ai/news/MU:1790861542656 2026-10-01T13:32:22.656Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud TD Cowen Reiterates Buy on Micron Technology, Maintains $1600 Price Target TD Cowen analyst Krish Sankar has reiterated a Buy rating on Micron Technology (NASDAQ: MU) and has maintained a price target of $1600 for the stock. This endorsement suggests confidence in Micron's performance and potential growth in the market. https://openbell.ai/news/BOSC:1790861499607 2026-10-01T13:31:39.607Z daily 0.9 https://cdn.brandfetch.io/BOSC/w/400/h/400?c=1idopYfmtR7ZKg8QMud BOS Better Online Solutions Awarded $380K Order From Undisclosed Israeli Defense Client BOS Better Online Solutions Ltd. (NASDAQ: BOSC) has announced a follow-on order worth $380,000 from an undisclosed existing client in the Israeli defense sector. This order comes from the company's Intelligent Robotics Division, which focuses on supply chain technologies for various industries including aerospace and defense. https://openbell.ai/news/MCK:1790861435583 2026-10-01T13:30:35.583Z daily 0.9 https://cdn.brandfetch.io/MCK/w/400/h/400?c=1idopYfmtR7ZKg8QMud McKesson shares are trading higher after the company reiterated its FY27 adjusted EPS guidance. openbell Financial News https://openbell.ai/news/TDEM:1790861404397 2026-10-01T13:30:04.397Z daily 0.9 https://cdn.brandfetch.io/TDEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halt status updated at 9:30:00 AM ET: Quotation Resumption: IPO security released for quotation openbell Financial News https://openbell.ai/news/TEVA:1790861328150 2026-10-01T13:28:48.150Z daily 0.9 https://cdn.brandfetch.io/TEVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud TD Cowen Initiates Coverage On Teva Pharmaceutical Indus with Buy Rating, Announces Price Target of $55 TD Cowen has initiated coverage on Teva Pharmaceutical Industries (NYSE: TEVA) with a Buy rating. The firm has set a price target of $55 for the company's stock. https://openbell.ai/news/TSLA:1790861316965 2026-10-01T13:28:36.965Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/01/Tesla-EV-electric-vehicle-Service-Center.jpg?width=250&height=187 Tesla Bears Retreat as Sell Ratings Hit 3-Year Low: 'Don't Bet Against Musk' Tesla Inc. (NASDAQ: TSLA) shares have declined approximately 19% this year, with sell ratings from analysts dropping to 13.1%, the lowest since April 2023, down from 23.3% in January. Analysts are increasingly valuing Tesla's potential in autonomy, robotics, and AI rather than just its automotive business, although hold-equivalent ratings are at a two-year high. The company is expected to report third-quarter deliveries of around 461,974, a 7% decrease from the previous year, with analysts adjusting their forecasts amid weaker vehicle trends in the U.S. and China. https://openbell.ai/news/XPEV:1790861267852 2026-10-01T13:27:47.852Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/01/Shanghai-china-april-27--2023-Xpeng-Car-.jpg?width=250&height=187 XPeng Delivers 118K EVs In Q3, Prepares Global G9L SUV Debut In Paris XPeng Inc. delivered 118,390 electric vehicles in Q3 2023, marking a 2.1% increase from the previous year and a 15% rise from Q2. In September alone, the company delivered 41,256 vehicles, slightly down from the same month last year but up 5% from August. XPeng is set to debut its G9L SUV at the Paris Motor Show, expanding its presence in Europe, and has also enhanced its charging network to cover over 430 cities in China with more than 4,000 stations. XPeng shares rose 0.84% in pre-market trading, reaching $9.64. https://openbell.ai/news/QNME:1790861237828 2026-10-01T13:27:17.828Z daily 0.9 https://cdn.brandfetch.io/QNME/w/400/h/400?c=1idopYfmtR7ZKg8QMud Quanome Technologies CEO Yang Li To Invest $15M In Non-Dilutive Growth Capital In Co. Quanome Technologies, Inc. (NASDAQ: QNME) has secured a revolving loan agreement with CEO and Chairman Yang Li for up to $15 million in non-dilutive growth capital. This funding will provide Quanome with additional resources to support its strategic initiatives in the quantum computing sector. https://openbell.ai/news/PFBC:1790861211463 2026-10-01T13:26:51.463Z daily 0.9 https://cdn.brandfetch.io/PFBC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Maintains Overweight on Preferred Bank, Raises Price Target to $120 Piper Sandler analyst Matthew Clark has maintained an Overweight rating on Preferred Bank (NASDAQ: PFBC) and increased the price target from $115 to $120. This adjustment reflects a positive outlook for the bank's performance. https://openbell.ai/news/AJG:1790861142425 2026-10-01T13:25:42.425Z daily 0.9 https://cdn.brandfetch.io/AJG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Arthur J. Gallagher Acquires Albany Insurance Services; Terms Not Disclosed Arthur J. Gallagher & Co. has acquired Albany Insurance Services Limited, a company based in New Zealand. The financial terms of the acquisition have not been disclosed. This move is part of Gallagher's strategy to expand its operations and services. https://openbell.ai/news/HXHX:1790861105929 2026-10-01T13:25:05.929Z daily 0.9 https://cdn.brandfetch.io/HXHX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Haoxin Holdings Announces Its Yiwu Haitong International Logistics Subsidiary Signed Agreement In September With Ningbo Zhongchong New Energy Automobile For 200 Battery-Swapping Electric Tractor Units For $18.02M Haoxin Holdings Limited (NASDAQ: HXHX) announced that its subsidiary, Yiwu Haitong International Logistics, signed a vehicle purchase agreement on September 12, 2026, with Ningbo Zhongchong New Energy Automobile for 200 battery-swapping electric tractor units. The total purchase price for this agreement is approximately RMB 120.9 million, equivalent to $18.02 million USD. This initiative is part of Haoxin's strategy to enhance its new energy logistics capabilities and transportation capacity. https://openbell.ai/news/UNH:1790861083946 2026-10-01T13:24:43.946Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/01/Jakarta---February-03-2023-Unitedhealthc.jpg?width=250&height=187 UnitedHealthcare Rolls Out 2027 Medicare Plans With $0 Premiums, Drug Copays And Broader Benefits UnitedHealthcare, a subsidiary of UnitedHealth Group Inc. (NYSE: UNH), has launched its 2027 Medicare Advantage plans, which include options with $0 premiums and drug copays, aiming to enhance accessibility for seniors. Over 94% of Medicare-eligible individuals will have access to these plans, with approximately 90% able to choose a $0 premium option. The plans also feature expanded benefits, including dental, vision, and hearing services, while maintaining $0 copays for primary care visits and preventive services. UnitedHealth shares were down 0.12% at $366.62 during premarket trading. https://openbell.ai/news/GANX:1790860848558 2026-10-01T13:20:48.558Z daily 0.9 https://cdn.brandfetch.io/GANX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year Gain Therapeutics (Ticker: GANX) announced plans to initiate a Phase 2 clinical trial for Rexaceract in the first quarter of next year. This trial is a significant step in the company's development pipeline, aiming to advance its therapeutic offerings. Further details regarding the trial's design and objectives were not disclosed in the announcement. https://openbell.ai/news/HPE:1790860752300 2026-10-01T13:19:12.300Z daily 0.9 https://cdn.brandfetch.io/HPE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hewlett Packard Enterprise shares are trading higher after multiple firms raised their respective price targets on the stock. openbell Financial News https://openbell.ai/news/CI:1790860691919 2026-10-01T13:18:11.919Z daily 0.9 https://cdn.brandfetch.io/CI/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Reiterates Outperform on Cigna Group, Maintains $337 Price Target RBC Capital analyst Ben Hendrix has reiterated an 'Outperform' rating on Cigna Group (NYSE: CI) and has maintained a price target of $337 for the stock. This endorsement suggests a positive outlook for Cigna Group's performance in the market. https://openbell.ai/news/BCDA:1790860665647 2026-10-01T13:17:45.647Z daily 0.9 https://cdn.brandfetch.io/BCDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart BioCardia, Inc. (NASDAQ: BCDA) has completed its revised Pre-Submission to the FDA's Center for Devices and Radiological Health under the Q-Submission program. This submission is aimed at obtaining approval for its Helix Catheter, which is designed for the delivery of therapeutic and diagnostic agents to the heart. https://openbell.ai/news/BE:1790860664856 2026-10-01T13:17:44.856Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/01/Bloom-Energy.jpg?width=250&height=187 Bloom Energy Stock Climbs Thursday: What's Going On? Bloom Energy Corp. (NYSE: BE) shares rose 3.08% to $285.50 in premarket trading on Thursday, continuing a strong upward trend after a 29% gain in September. Key drivers of this momentum included the company's inclusion in the S&P 500 effective September 21, a 158,000-square-foot expansion of its Fremont manufacturing facility, and reaffirmation of support for its 'Project Jupiter' by Oracle. Analysts have also raised their price targets for Bloom Energy, with Jefferies increasing its target from $229 to $264, reflecting a positive long-term growth outlook. https://openbell.ai/news/LTC:1790860631498 2026-10-01T13:17:11.498Z daily 0.9 https://cdn.brandfetch.io/LTC/w/400/h/400?c=1idopYfmtR7ZKg8QMud LTC Properties Announces ~$160M Of Acquisitions And Strategic Divestitures Of Two Non-SHOP Portfolios LTC Properties announced the acquisition of three senior housing communities for nearly $160 million, including a $69 million community in Florida and two communities in Virginia and Maryland for $89 million. The company also divested two non-SHOP portfolios, generating over $260 million in gross proceeds and an expected gain of approximately $225 million. LTC's SHOP platform has expanded significantly, now comprising 46 communities and contributing over 40% of its annualized net operating income, while the triple-net skilled nursing portfolio has decreased to about 30%. Year-to-date, LTC has completed around $740 million in SHOP acquisitions, nearing its 2026 acquisition target. https://openbell.ai/news/BCDA:1790860598914 2026-10-01T13:16:38.914Z daily 0.9 https://cdn.brandfetch.io/BCDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart BioCardia, Inc. (NASDAQ: BCDA) has completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health under its Q-Submission program. This submission is for the approval of its Helix Catheter, which is designed for the delivery of therapeutic and diagnostic agents to the heart. https://openbell.ai/news/RKLB:1790860570000 2026-10-01T13:16:10.000Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/01/Konskie--Poland---March-01--2025-Rocket-.jpg?width=250&height=187 Rocket Lab’s 20-Launch Synspective Deal Pushes Backlog Above 100 Missions Rocket Lab Corp has secured a 20-launch agreement with Japan's Synspective, increasing its total bookings to 47 missions and pushing its launch backlog above 100. The multi-year contract involves launching StriX synthetic aperture radar satellites from 2028 to 2031. Following the announcement, Rocket Lab's shares rose over 5% in premarket trading. Additionally, the company is progressing with its $8 billion acquisition of Iridium, which received shareholder approval, and anticipates a revenue increase to approximately $238.53 million in its upcoming earnings report. https://openbell.ai/news/HDB:1790860452508 2026-10-01T13:14:12.508Z daily 0.9 https://cdn.brandfetch.io/HDB/w/400/h/400?c=1idopYfmtR7ZKg8QMud HDFC Bank Appoints ​Anup Bagchi As Managing Director And CEO For A Term Of Three Years, Effective October 27 openbell Financial News https://openbell.ai/news/SWKS:1790860450868 2026-10-01T13:14:10.868Z daily 0.9 https://cdn.brandfetch.io/SWKS/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Maintains Sector Perform on Skyworks Solutions, Raises Price Target to $95 RBC Capital analyst Srini Pajjuri has maintained a 'Sector Perform' rating on Skyworks Solutions (NASDAQ: SWKS) and raised the price target from $70 to $95. This adjustment reflects a positive outlook for the company's performance in the market. https://openbell.ai/news/MU:1790860302101 2026-10-01T13:11:42.101Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Reiterates Outperform on Micron Technology, Maintains $1500 Price Target RBC Capital analyst Srini Pajjuri has reiterated an 'Outperform' rating on Micron Technology (NASDAQ: MU) and has maintained a price target of $1500 for the stock. This endorsement suggests confidence in Micron's performance in the market. https://openbell.ai/news/RKLB:1790860264703 2026-10-01T13:11:04.703Z daily 0.9 https://cdn.brandfetch.io/RKLB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rocket Lab shares are trading higher after the company announced it signed a multi-year launch agreement for 20 new Electron missions with Synspective. openbell Financial News https://openbell.ai/news/SINT:1790860235786 2026-10-01T13:10:35.786Z daily 0.9 https://cdn.brandfetch.io/SINT/w/400/h/400?c=1idopYfmtR7ZKg8QMud SINTX Reports Preliminary Q3 Revenue of $2.2M, Exceeding High End Of Company’s Previously Announced Guidance Of $0.9M-$1.1M SINTX Technologies, Inc. reported preliminary Q3 revenue of $2.2 million, significantly exceeding its previous guidance of $0.9 million to $1.1 million, marking a 380% increase from Q2. The revenue growth was primarily driven by strong industrial sales to Fortune 500 customers, particularly in aerospace. The company also announced that this revenue milestone allows it to call Class B warrants and reiterated its Q4 revenue guidance. https://openbell.ai/news/MKC:1790860099794 2026-10-01T13:08:19.794Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/01/London--On--Canada---August-30--2020-Clo.jpg?width=250&height=187 McCormick on Track to Build $20 Billion Mega-Flavor Powerhouse With Unilever Deal McCormick & Company reported better-than-expected fiscal 2026 third-quarter results, with adjusted earnings of 86 cents per share, surpassing the analyst estimate of 76 cents. Net sales rose 17.4% year over year to $2.02 billion, exceeding the consensus estimate of $1.98 billion. The company reaffirmed its fiscal 2026 outlook, expecting revenue between $7.729 billion and $8.003 billion, and is on track with its proposed combination with Unilever's Foods business, which aims to create a $20 billion global flavor company by mid-2027. https://openbell.ai/news/OTLK:1790860093278 2026-10-01T13:08:13.278Z daily 0.9 https://cdn.brandfetch.io/OTLK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration Outlook Therapeutics, Inc. (Nasdaq: OTLK) has filed an application with the Centers for Medicare & Medicaid Services (CMS) for a permanent Healthcare Common Procedure Coding System (HCPCS) Level II J-code for its product LYTENAVA, aimed at treating wet age-related macular degeneration. This submission is part of the company's strategy to enhance U.S. commercialization and market access for LYTENAVA, which is the only FDA-approved ophthalmic bevacizumab for this condition. Outlook Therapeutics is targeting a commercial launch of LYTENAVA before the end of 2026. https://openbell.ai/news/INSP:1790860088167 2026-10-01T13:08:08.167Z daily 0.9 https://cdn.brandfetch.io/INSP/w/400/h/400?c=1idopYfmtR7ZKg8QMud RBC Capital Maintains Sector Perform on Inspire Medical Systems, Raises Price Target to $75 RBC Capital analyst Kendall Au has maintained a 'Sector Perform' rating on Inspire Medical Systems (NYSE: INSP) and increased the price target from $60 to $75. This adjustment reflects a positive outlook for the company within its sector.